A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

Type of Cancer
Breast Oncology

Phase

Division (Location)

Study ID

NCT#

Brief Description
A randomized, double-blind, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for Metastatic Triple-Negative Breast Cancer (FRIDA)

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.